Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in ...
Q1 2026
May 13, 2026
FY 2025
Mar 25, 2026
Q4 2025
Q3 2025
Nov 13, 2025
Q2 2025
Aug 14, 2025